News
(2)April 2026
KROS Proxy Statement details $375 million capital return and clinical focus
# 📜 What This Document Is 📜 This document is Keros Therapeutics, Inc.'s (KROS) definitive Proxy Statement for the 2026 Annual Meeting of Stockholders. Essentially, it is a formal annual report that tells you exactly what the company is doing, who is running it, and—most importantly—what decisions
Please provide the actual text content of the SEC filing for headline generation
Please provide the actual content of the SEC filing. The input you provided is a placeholder structure (metadata) indicating that the document is an Annual Report Summary (ARS) for Keros Therapeutics, Inc., but the PDF content itself is empty. Once you provide the text or the full PDF, I will exec
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.